Annals of the New York Academy of Sciences

Cover image for Annals of the New York Academy of Sciences

May 1998

Volume 840 NEUROIMMUNOMODULATION: MOLECULAR ASPECTS, INTEGRATIVE SYSTEMS, AND CLINICAL ADVANCES

Pages xiii–xiv, 1–856

  1. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Introduction

    1. Top of page
    2. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Introduction
    3. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: New Perspectives in Neuroimmunomodulation
    4. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    5. Article: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    6. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    7. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advances: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    8. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    9. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Sex Hormones, NOS, and Immunity
    10. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Nervous System Inputs to Inflammation
    11. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Apoptosis, Glucocorticoids, and Thymic Immunity
    12. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Melatonin, MSH, Opiates, and Immune Function
    13. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Hypothalamic-Pituitary-Adrenal Axis and Glucocorticoids
    14. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Thymus-Neuroendocrine Interactions
    15. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Growth Hormone, Prolactin, and POMC
    16. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: VIP, Substance P, and Calcitonin
    17. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications
    18. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Behavior and the Immune System: Animal Models
    19. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Human Behavior and Immune Responses
    20. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Inflammatory Diseases: Human and Animal Models
    21. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Allergic Disease
    22. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Infectious Diseases
    1. Introduction (pages xiii–xiv)

      S. M. McCANN

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09542.x

  2. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: New Perspectives in Neuroimmunomodulation

    1. Top of page
    2. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Introduction
    3. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: New Perspectives in Neuroimmunomodulation
    4. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    5. Article: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    6. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    7. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advances: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    8. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    9. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Sex Hormones, NOS, and Immunity
    10. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Nervous System Inputs to Inflammation
    11. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Apoptosis, Glucocorticoids, and Thymic Immunity
    12. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Melatonin, MSH, Opiates, and Immune Function
    13. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Hypothalamic-Pituitary-Adrenal Axis and Glucocorticoids
    14. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Thymus-Neuroendocrine Interactions
    15. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Growth Hormone, Prolactin, and POMC
    16. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: VIP, Substance P, and Calcitonin
    17. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications
    18. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Behavior and the Immune System: Animal Models
    19. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Human Behavior and Immune Responses
    20. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Inflammatory Diseases: Human and Animal Models
    21. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Allergic Disease
    22. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Infectious Diseases
    1. Introduction: Overview of the Conference and the Field (pages 1–8)

      ESTHER M. STERNBERG

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09543.x

    2. Opiate Inhibition of Chemokine-Induced Chemotaxis (pages 9–20)

      M. C. GRIMM, A. BEN-BARUCH, D. D. TAUB, O. M. Z. HOWARD, J. M. WANG and J. J. OPPENHEIM

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09544.x

    3. Corticotropin-Releasing Hormone and Inflammation (pages 21–32)

      ELIZABETH L. WEBSTER, DAVID J. TORPY, ILIA J. ELENKOV and GEORGE P. CHROUSOS

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09545.x

    4. Hormones, Pregnancy, and Autoimmune Diseases (pages 45–50)

      RONALD L. WILDER

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09547.x

  3. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System

    1. Top of page
    2. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Introduction
    3. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: New Perspectives in Neuroimmunomodulation
    4. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    5. Article: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    6. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    7. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advances: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    8. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    9. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Sex Hormones, NOS, and Immunity
    10. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Nervous System Inputs to Inflammation
    11. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Apoptosis, Glucocorticoids, and Thymic Immunity
    12. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Melatonin, MSH, Opiates, and Immune Function
    13. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Hypothalamic-Pituitary-Adrenal Axis and Glucocorticoids
    14. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Thymus-Neuroendocrine Interactions
    15. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Growth Hormone, Prolactin, and POMC
    16. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: VIP, Substance P, and Calcitonin
    17. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications
    18. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Behavior and the Immune System: Animal Models
    19. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Human Behavior and Immune Responses
    20. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Inflammatory Diseases: Human and Animal Models
    21. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Allergic Disease
    22. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Infectious Diseases
    1. Contribution of the ICE Family to Neurodegeneration (pages 59–64)

      BRENDA D. SHIVERS, PETER A. BOXER, KAREN M. KEANE, NANCY C. KUPINA, TONI LYNCH, GERALD P. SCHIELKE, MARK G. VARTANIAN and JOHN P. VASILAKOS

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09549.x

  4. Article: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System

    1. Top of page
    2. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Introduction
    3. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: New Perspectives in Neuroimmunomodulation
    4. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    5. Article: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    6. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    7. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advances: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    8. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    9. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Sex Hormones, NOS, and Immunity
    10. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Nervous System Inputs to Inflammation
    11. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Apoptosis, Glucocorticoids, and Thymic Immunity
    12. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Melatonin, MSH, Opiates, and Immune Function
    13. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Hypothalamic-Pituitary-Adrenal Axis and Glucocorticoids
    14. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Thymus-Neuroendocrine Interactions
    15. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Growth Hormone, Prolactin, and POMC
    16. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: VIP, Substance P, and Calcitonin
    17. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications
    18. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Behavior and the Immune System: Animal Models
    19. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Human Behavior and Immune Responses
    20. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Inflammatory Diseases: Human and Animal Models
    21. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Allergic Disease
    22. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Infectious Diseases
    1. Interleukin-3 and Interleukin-3 Receptors in the Brain (pages 107–116)

      TAKESHI TABIRA, DE-HUA CHUI, JI-PING FAN, TERUO SHIRABE and YOSHIHIRO KONISHI

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09554.x

  5. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function

    1. Top of page
    2. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Introduction
    3. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: New Perspectives in Neuroimmunomodulation
    4. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    5. Article: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    6. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    7. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advances: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    8. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    9. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Sex Hormones, NOS, and Immunity
    10. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Nervous System Inputs to Inflammation
    11. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Apoptosis, Glucocorticoids, and Thymic Immunity
    12. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Melatonin, MSH, Opiates, and Immune Function
    13. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Hypothalamic-Pituitary-Adrenal Axis and Glucocorticoids
    14. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Thymus-Neuroendocrine Interactions
    15. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Growth Hormone, Prolactin, and POMC
    16. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: VIP, Substance P, and Calcitonin
    17. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications
    18. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Behavior and the Immune System: Animal Models
    19. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Human Behavior and Immune Responses
    20. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Inflammatory Diseases: Human and Animal Models
    21. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Allergic Disease
    22. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Infectious Diseases
    1. Interleukin-1, but Not Stress, Stimulates Glucocorticoid Output during Early Postnatal Life in Mice (pages 117–122)

      HIROMU FURUKAWA, ADRIANA DEL REY, GABRIELA MONGE-ARDITI and HUGO O. BESEDOVSKY

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09555.x

    2. Administration of Interleukin-1 at Birth Affects Dopaminergic Neurons in Adult Mice (pages 123–127)

      ALEXA KABIERSCH, HIROMU FURUKAWA, ADRIANA DEL REY and H. O. BESEDOVSKY

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09556.x

  6. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advances: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function

    1. Top of page
    2. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Introduction
    3. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: New Perspectives in Neuroimmunomodulation
    4. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    5. Article: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    6. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    7. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advances: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    8. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    9. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Sex Hormones, NOS, and Immunity
    10. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Nervous System Inputs to Inflammation
    11. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Apoptosis, Glucocorticoids, and Thymic Immunity
    12. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Melatonin, MSH, Opiates, and Immune Function
    13. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Hypothalamic-Pituitary-Adrenal Axis and Glucocorticoids
    14. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Thymus-Neuroendocrine Interactions
    15. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Growth Hormone, Prolactin, and POMC
    16. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: VIP, Substance P, and Calcitonin
    17. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications
    18. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Behavior and the Immune System: Animal Models
    19. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Human Behavior and Immune Responses
    20. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Inflammatory Diseases: Human and Animal Models
    21. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Allergic Disease
    22. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Infectious Diseases
    1. Effects of Peripheral Administration of LPS on the Expression of Immunoreactive Interleukin-1α, β, and Receptor Antagonist in Rat Brain (pages 128–138)

      ANNE-MARIE VAN DAM, STEPHEN POOLE, MARIANNE SCHULTZBERG, FLORA ZAVALA and FRED J. H. TILDERS

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09557.x

  7. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function

    1. Top of page
    2. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Introduction
    3. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: New Perspectives in Neuroimmunomodulation
    4. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    5. Article: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    6. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    7. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advances: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    8. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    9. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Sex Hormones, NOS, and Immunity
    10. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Nervous System Inputs to Inflammation
    11. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Apoptosis, Glucocorticoids, and Thymic Immunity
    12. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Melatonin, MSH, Opiates, and Immune Function
    13. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Hypothalamic-Pituitary-Adrenal Axis and Glucocorticoids
    14. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Thymus-Neuroendocrine Interactions
    15. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Growth Hormone, Prolactin, and POMC
    16. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: VIP, Substance P, and Calcitonin
    17. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications
    18. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Behavior and the Immune System: Animal Models
    19. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Human Behavior and Immune Responses
    20. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Inflammatory Diseases: Human and Animal Models
    21. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Allergic Disease
    22. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Infectious Diseases
    1. Brain Neurotransmission during Peripheral Inflammation (pages 139–152)

      ASTRID C. E. LINTHORST and JOHANNES M. H. M. REUL

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09558.x

    2. Central and Peripheral Mechanisms Contribute to the Hypoglycemia Induced by Interleukin-1 (pages 153–161)

      ADRIANA DEL REY, GABRIELA MONGE-ARDITI and HUGO O. BESEDOVSKY

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09559.x

    3. Leukemia Inhibitory Factor Regulates Proopiomelanocortin Transcription (pages 162–173)

      DAVID W. RAY, SONG-GUANG REN and SHLOMO MELMED

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09560.x

  8. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Sex Hormones, NOS, and Immunity

    1. Top of page
    2. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Introduction
    3. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: New Perspectives in Neuroimmunomodulation
    4. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    5. Article: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    6. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    7. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advances: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    8. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    9. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Sex Hormones, NOS, and Immunity
    10. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Nervous System Inputs to Inflammation
    11. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Apoptosis, Glucocorticoids, and Thymic Immunity
    12. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Melatonin, MSH, Opiates, and Immune Function
    13. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Hypothalamic-Pituitary-Adrenal Axis and Glucocorticoids
    14. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Thymus-Neuroendocrine Interactions
    15. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Growth Hormone, Prolactin, and POMC
    16. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: VIP, Substance P, and Calcitonin
    17. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications
    18. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Behavior and the Immune System: Animal Models
    19. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Human Behavior and Immune Responses
    20. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Inflammatory Diseases: Human and Animal Models
    21. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Allergic Disease
    22. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Infectious Diseases
    1. Role of Nitric Oxide in the Neuroendocrine Responses to Cytokines (pages 174–184)

      S. M. McCANN, M. KIMURA, S. KARANTH, W. H. YU and V. RETTORI

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09561.x

    2. The Role of IL-6 Type Cytokines and Their Receptors in Bonea (pages 194–204)

      STAVROS C. MANOLAGAS

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09563.x

    3. Luteinizing Hormone-Releasing Hormone Is a Primary Signaling Molecule in the Neuroimmune Network (pages 205–248)

      BIANCA MARCHETTI, FRANCESCO GALLO, ZELINDA FARINELLA, CATALDO TIROLO, NUCCIO TESTA, CARMELA ROMEO and MARIA C. MORALE

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09564.x

    4. Acute and Subacute Effects of Endotoxin on Hypothalamic Gaseous Neuromodulators (pages 249–261)

      I. KOSTOGLOU-ATHANASSIOU, R. A. JACOBS, M. A. SATTA, P. L. M. DAHIA, A. COSTA, P. NAVARRA, S. L. CHEW, M. L. FORSLING and A. B. GROSSMAN

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09565.x

  9. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Nervous System Inputs to Inflammation

    1. Top of page
    2. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Introduction
    3. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: New Perspectives in Neuroimmunomodulation
    4. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    5. Article: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    6. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    7. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advances: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    8. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    9. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Sex Hormones, NOS, and Immunity
    10. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Nervous System Inputs to Inflammation
    11. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Apoptosis, Glucocorticoids, and Thymic Immunity
    12. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Melatonin, MSH, Opiates, and Immune Function
    13. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Hypothalamic-Pituitary-Adrenal Axis and Glucocorticoids
    14. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Thymus-Neuroendocrine Interactions
    15. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Growth Hormone, Prolactin, and POMC
    16. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: VIP, Substance P, and Calcitonin
    17. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications
    18. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Behavior and the Immune System: Animal Models
    19. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Human Behavior and Immune Responses
    20. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Inflammatory Diseases: Human and Animal Models
    21. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Allergic Disease
    22. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Infectious Diseases
    1. Alterations in Sympathetic Noradrenergic Innervation in Lymphoid Organs with Age (pages 262–268)

      KELLEY S. MADDEN, S. THYAGARAJAN and DAVID L. FELTEN

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09566.x

    2. Pain Modulatory Actions of Cytokines and Prostaglandin E2 in the Brain (pages 269–281)

      T. HORI, T. OKA, M. HOSOI and S. AOU

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09567.x

    3. Endocrine and Vagal Controls of Sympathetically Dependent Neurogenic Inflammation (pages 282–288)

      PAUL G. GREEN, FREDERICK JIA-PEI MIAO, HOLLY STRAUSBAUGH, PHILIP HELLER, WILFRID JANIG and JON D. LEVINE

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09568.x

    4. The Role of the Vagus Nerve in Cytokine-to-Brain Communication (pages 289–300)

      STEVEN F. MAIER, LISA E. GOEHLER, MONIKA FLESHNER and LINDA R. WATKINS

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09569.x

  10. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Apoptosis, Glucocorticoids, and Thymic Immunity

    1. Top of page
    2. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Introduction
    3. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: New Perspectives in Neuroimmunomodulation
    4. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    5. Article: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    6. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    7. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advances: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    8. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    9. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Sex Hormones, NOS, and Immunity
    10. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Nervous System Inputs to Inflammation
    11. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Apoptosis, Glucocorticoids, and Thymic Immunity
    12. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Melatonin, MSH, Opiates, and Immune Function
    13. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Hypothalamic-Pituitary-Adrenal Axis and Glucocorticoids
    14. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Thymus-Neuroendocrine Interactions
    15. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Growth Hormone, Prolactin, and POMC
    16. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: VIP, Substance P, and Calcitonin
    17. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications
    18. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Behavior and the Immune System: Animal Models
    19. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Human Behavior and Immune Responses
    20. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Inflammatory Diseases: Human and Animal Models
    21. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Allergic Disease
    22. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Infectious Diseases
    1. A Positive Role for Thymus-Derived Steroids in Formation of the T-Cell Repertoire (pages 317–327)

      MELANIE S. VACCHIO, JONATHAN D. ASHWELL and LESLIE B. KING

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09571.x

    2. Cellular and Molecular Aspects of Thymic T-Cell Education in Neuroendocrine Self Principles: Implications for Autoimmunity (pages 328–337)

      VINCENT GEENEN, HENRI MARTENS, ERIC VANDERSMISSEN, IMANE ACHOUR, OUAFAE KECHA and DENIS FRANCHIMONT

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09572.x

    3. Regulation of Inhibitory Pathways of the Interleukin-1 System (pages 338–351)

      A. MANTOVANI, M. MUZIO, P. GHEZZI, C. COLOTTA and M. INTRONA

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09573.x

    4. Thymic Endocrinology (pages 352–358)

      JOHN W. HADDEN

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09574.x

    5. Stress-Induced Enhancement of Cell-Mediated Immunity (pages 359–372)

      FIRDAUS S. DHABHAR

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09575.x

  11. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Melatonin, MSH, Opiates, and Immune Function

    1. Top of page
    2. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Introduction
    3. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: New Perspectives in Neuroimmunomodulation
    4. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    5. Article: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    6. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    7. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advances: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    8. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    9. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Sex Hormones, NOS, and Immunity
    10. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Nervous System Inputs to Inflammation
    11. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Apoptosis, Glucocorticoids, and Thymic Immunity
    12. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Melatonin, MSH, Opiates, and Immune Function
    13. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Hypothalamic-Pituitary-Adrenal Axis and Glucocorticoids
    14. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Thymus-Neuroendocrine Interactions
    15. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Growth Hormone, Prolactin, and POMC
    16. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: VIP, Substance P, and Calcitonin
    17. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications
    18. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Behavior and the Immune System: Animal Models
    19. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Human Behavior and Immune Responses
    20. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Inflammatory Diseases: Human and Animal Models
    21. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Allergic Disease
    22. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Infectious Diseases
    1. Mechanisms of Antiinflammatory Action of the Neuroimmunomodulatory Peptide α-MSH (pages 373–380)

      JAMES M. LIPTON and ANNA CATANIA

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09576.x

    2. Cutaneous Immunomodulation and Coordination of Skin Stress Responses by α-Melanocyte-Stimulating Hormone (pages 381–394)

      THOMAS A. LUGER, THOMAS SCHOLZEN, THOMAS BRZOSKA, EVA BECHER, ANDRZEJ SLOMINSKI and RALF PAUS

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09577.x

    3. Melatonin Rhythms in Mice: Role in Autoimmune and Lymphoproliferative Diseases (pages 395–410)

      ARIO CONTI and GEORGES J. M. MAESTRONI

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09578.x

    4. Signaling through Delta Opioid Receptors on Murine Splenic T Cells and Stably Transfected Jurkat Cells (pages 420–424)

      BURT M. SHARP, DAVID J. McKEAN, KATHY McALLEN and NAHID A. SHAHABI

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09580.x

  12. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Hypothalamic-Pituitary-Adrenal Axis and Glucocorticoids

    1. Top of page
    2. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Introduction
    3. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: New Perspectives in Neuroimmunomodulation
    4. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    5. Article: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    6. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    7. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advances: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    8. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    9. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Sex Hormones, NOS, and Immunity
    10. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Nervous System Inputs to Inflammation
    11. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Apoptosis, Glucocorticoids, and Thymic Immunity
    12. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Melatonin, MSH, Opiates, and Immune Function
    13. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Hypothalamic-Pituitary-Adrenal Axis and Glucocorticoids
    14. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Thymus-Neuroendocrine Interactions
    15. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Growth Hormone, Prolactin, and POMC
    16. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: VIP, Substance P, and Calcitonin
    17. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications
    18. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Behavior and the Immune System: Animal Models
    19. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Human Behavior and Immune Responses
    20. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Inflammatory Diseases: Human and Animal Models
    21. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Allergic Disease
    22. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Infectious Diseases
    1. Mechanisms of Hypothalamic-Pituitary-Adrenal Axis Stimulation by Immune Signals in the Adult Rat (pages 434–443)

      ANDREW V. TURNBULL, SOON LEE and CATHERINE RIVIER

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09582.x

    2. Altered Neuroimmunoendocrine Communication during a Condition of Chronically Increased Brain Corticotropin-Releasing Hormone Drive (pages 444–455)

      JOHANNES M. H. M. REUL, MARTA S. LABEUR, G. JAN WIEGERS and ASTRID C. E. LINTHORST

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09583.x

    3. A Novel Endogenous Corticotropin Release Inhibiting Factor (pages 456–469)

      EVA REDEI, PETER A. RITTENHOUSE, SERGEI REVSKOY, ROBERT F. McGIVERN and FRASER AIRD

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09584.x

  13. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Thymus-Neuroendocrine Interactions

    1. Top of page
    2. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Introduction
    3. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: New Perspectives in Neuroimmunomodulation
    4. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    5. Article: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    6. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    7. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advances: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    8. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    9. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Sex Hormones, NOS, and Immunity
    10. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Nervous System Inputs to Inflammation
    11. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Apoptosis, Glucocorticoids, and Thymic Immunity
    12. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Melatonin, MSH, Opiates, and Immune Function
    13. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Hypothalamic-Pituitary-Adrenal Axis and Glucocorticoids
    14. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Thymus-Neuroendocrine Interactions
    15. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Growth Hormone, Prolactin, and POMC
    16. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: VIP, Substance P, and Calcitonin
    17. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications
    18. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Behavior and the Immune System: Animal Models
    19. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Human Behavior and Immune Responses
    20. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Inflammatory Diseases: Human and Animal Models
    21. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Allergic Disease
    22. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Infectious Diseases
    1. Neuroendocrine Control of the Thymus (pages 470–479)

      WILSON SAVINO, DÉA MARIA SERRA VILLA-VERDE, LUIZ ANASTACIO ALVES and MIREILLE DARDENNE

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09585.x

    2. Neuroimmunomodulation of Aging: A Program in the Pineal Gland (pages 491–497)

      WALTER PIERPAOLI

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09587.x

  14. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Growth Hormone, Prolactin, and POMC

    1. Top of page
    2. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Introduction
    3. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: New Perspectives in Neuroimmunomodulation
    4. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    5. Article: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    6. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    7. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advances: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    8. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    9. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Sex Hormones, NOS, and Immunity
    10. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Nervous System Inputs to Inflammation
    11. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Apoptosis, Glucocorticoids, and Thymic Immunity
    12. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Melatonin, MSH, Opiates, and Immune Function
    13. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Hypothalamic-Pituitary-Adrenal Axis and Glucocorticoids
    14. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Thymus-Neuroendocrine Interactions
    15. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Growth Hormone, Prolactin, and POMC
    16. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: VIP, Substance P, and Calcitonin
    17. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications
    18. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Behavior and the Immune System: Animal Models
    19. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Human Behavior and Immune Responses
    20. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Inflammatory Diseases: Human and Animal Models
    21. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Allergic Disease
    22. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Infectious Diseases
    1. Prolactin: A Hormone at the Crossroads of Neuroimmunoendocrinology (pages 498–509)

      VINCENT GOFFIN, BRIGITTE BOUCHARD, CHRISTOPHER J. ORMANDY, EDDA WEIMANN, FATIMA FERRAG, PHILIPPE TOURAINE, CHRISTINE BOLE-FEYSOT, RONDA A. MAASKANT, PHILIPPE CLEMENT-LACROIX, MARC EDERY, NADINE BINART and PAUL A. KELLY

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09588.x

    2. Growth Hormone Receptors and Immunocompetent Cells (pages 510–517)

      M. DARDENNE, V. MELLO-COELHO, M. C. GAGNERAULT and M. C. POSTEL-VINAY

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09589.x

    3. Insulin Growth Factor-I Inhibits Apoptosis in Hematopoietic: Progenitor Cells Implications in Thymic Aging (pages 518–524)

      KEITH W. KELLEY, WILLIAM A. MEIER, CHRISTIAN MINSHALL, DANIEL H. SCHACHER, QIANG LIU, ROGER VANHOY, WILLIAM BURGESS and ROBERT DANTZER

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09590.x

    4. Cytokine Expression and Molecular Mechanisms of Their Auto/Paracrine Regulation of Anterior Pituitary Function and Growth (pages 525–531)

      E. ARZT, M. PÁEZ PEREDA, M. COSTAS, J. SAUER, U. RENNER, F. HOLSBOER and G. K. STALLA

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09591.x

  15. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: VIP, Substance P, and Calcitonin

    1. Top of page
    2. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Introduction
    3. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: New Perspectives in Neuroimmunomodulation
    4. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    5. Article: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    6. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    7. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advances: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    8. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    9. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Sex Hormones, NOS, and Immunity
    10. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Nervous System Inputs to Inflammation
    11. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Apoptosis, Glucocorticoids, and Thymic Immunity
    12. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Melatonin, MSH, Opiates, and Immune Function
    13. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Hypothalamic-Pituitary-Adrenal Axis and Glucocorticoids
    14. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Thymus-Neuroendocrine Interactions
    15. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Growth Hormone, Prolactin, and POMC
    16. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: VIP, Substance P, and Calcitonin
    17. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications
    18. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Behavior and the Immune System: Animal Models
    19. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Human Behavior and Immune Responses
    20. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Inflammatory Diseases: Human and Animal Models
    21. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Allergic Disease
    22. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Infectious Diseases
    1. The Substance P and Somatostatin Interferon-γ Immunoregulatory Circuit (pages 532–539)

      JOEL V. WEINSTOCK and DAVID ELLIOTT

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09592.x

    2. Selectivity of Effects of Vasoactive Intestinal Peptide on Macrophages and Lymphocytes in Compartmental Immune Responses (pages 540–550)

      EDWARD J. GOETZL, RAVI R. PANKHANIYA, GARY O. GAUFO, YAJUN MU, MENGHANG XIA and SUNIL P. SREEDHARAN

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09593.x

  16. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications

    1. Top of page
    2. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Introduction
    3. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: New Perspectives in Neuroimmunomodulation
    4. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    5. Article: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    6. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    7. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advances: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    8. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    9. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Sex Hormones, NOS, and Immunity
    10. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Nervous System Inputs to Inflammation
    11. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Apoptosis, Glucocorticoids, and Thymic Immunity
    12. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Melatonin, MSH, Opiates, and Immune Function
    13. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Hypothalamic-Pituitary-Adrenal Axis and Glucocorticoids
    14. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Thymus-Neuroendocrine Interactions
    15. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Growth Hormone, Prolactin, and POMC
    16. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: VIP, Substance P, and Calcitonin
    17. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications
    18. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Behavior and the Immune System: Animal Models
    19. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Human Behavior and Immune Responses
    20. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Inflammatory Diseases: Human and Animal Models
    21. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Allergic Disease
    22. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Infectious Diseases
  17. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Behavior and the Immune System: Animal Models

    1. Top of page
    2. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Introduction
    3. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: New Perspectives in Neuroimmunomodulation
    4. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    5. Article: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    6. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    7. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advances: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    8. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    9. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Sex Hormones, NOS, and Immunity
    10. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Nervous System Inputs to Inflammation
    11. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Apoptosis, Glucocorticoids, and Thymic Immunity
    12. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Melatonin, MSH, Opiates, and Immune Function
    13. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Hypothalamic-Pituitary-Adrenal Axis and Glucocorticoids
    14. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Thymus-Neuroendocrine Interactions
    15. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Growth Hormone, Prolactin, and POMC
    16. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: VIP, Substance P, and Calcitonin
    17. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications
    18. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Behavior and the Immune System: Animal Models
    19. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Human Behavior and Immune Responses
    20. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Inflammatory Diseases: Human and Animal Models
    21. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Allergic Disease
    22. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Infectious Diseases
    1. The Role of Cytokines in Infection-Related Behavior (pages 577–585)

      ADRIAN J. DUNN and ARTUR H. SWIERGIEL

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09596.x

    2. Cytokines and Sickness Behavior (pages 586–590)

      ROBERT DANTZER, ROSE-MARIE BLUTHÉ, SOPHIE LAYÉ, JEAN-LUC BRET-DIBAT, PATRICIA PARNET and KEITH W. KELLEY

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09597.x

    3. Neuroendocrine-Immune Disturbances in Animal Models with Spontaneous Autoimmune Diseases (pages 591–598)

      GEORG WICK, ROSWITHA SGONC and OSKAR LECHNER

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09598.x

    4. Inflammatory Disease as Chronic Stress (pages 599–607)

      N. SHANKS, M. S. HARBUZ, D. S. JESSOP, P. PERKS, P. M. MOORE and S. L. LIGHTMAN

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09599.x

    5. Cytokines and Fever (pages 608–618)

      CLARK M. BLATTEIS and ELMIR SEHIC

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09600.x

    6. Interstitial Cystitis: A Neuroimmunoendocrine Disorder (pages 619–634)

      THEOHARIDES C. THEOHARIDES, XINZHU PANG, RICHARD LETOURNEAU and GRANNUM R. SANT

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09601.x

    7. Neuroimmune Mechanisms of Intestinal Responses to Stress: Role of Corticotropin-Releasing Factor and Neurotensin (pages 635–648)

      CHARALABOS POTHOULAKIS, IGNAZIO CASTAGLIUOLO and SUSAN E. LEEMAN

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09602.x

  18. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Human Behavior and Immune Responses

    1. Top of page
    2. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Introduction
    3. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: New Perspectives in Neuroimmunomodulation
    4. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    5. Article: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    6. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    7. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advances: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    8. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    9. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Sex Hormones, NOS, and Immunity
    10. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Nervous System Inputs to Inflammation
    11. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Apoptosis, Glucocorticoids, and Thymic Immunity
    12. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Melatonin, MSH, Opiates, and Immune Function
    13. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Hypothalamic-Pituitary-Adrenal Axis and Glucocorticoids
    14. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Thymus-Neuroendocrine Interactions
    15. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Growth Hormone, Prolactin, and POMC
    16. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: VIP, Substance P, and Calcitonin
    17. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications
    18. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Behavior and the Immune System: Animal Models
    19. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Human Behavior and Immune Responses
    20. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Inflammatory Diseases: Human and Animal Models
    21. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Allergic Disease
    22. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Infectious Diseases
    1. The Influence of Psychological Stress on the Immune Response to Vaccines (pages 649–655)

      RONALD GLASER, JANICE K. KIECOLT-GLASER, WILLIAM B. MALARKEY and JOHN F. SHERIDAN

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09603.x

    2. Marital Stress: Immunologic, Neuroendocrine, and Autonomic Correlates (pages 656–663)

      JANICE K. KIECOLT-GLASER, RONALD GLASER, JOHN T. CACIOPPO and WILLIAM B. MALARKEY

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09604.x

    3. Autonomic, Neuroendocrine, and Immune Responses to Psychological Stress: The Reactivity Hypothesis (pages 664–673)

      JOHN T. CACIOPPO, GARY G. BERNTSON, WILLIAM B. MALARKEY, JANICE K. KIECOLT-GLASER, JOHN F. SHERIDAN, KIRSTEN M. POEHLMANN, MARY H. BURLESON, JOHN M. ERNST, LOUISE C. HAWKLEY and RONALD GLASER

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09605.x

    4. Effects of Psychosocial Treatment in Prolonging Cancer Survival May Be Mediated by Neuroimmune Pathways (pages 674–683)

      DAVID SPIEGEL, SANDRA E. SEPHTON, ABBA I. TERR and DANIEL P. STITES

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09606.x

  19. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Inflammatory Diseases: Human and Animal Models

    1. Top of page
    2. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Introduction
    3. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: New Perspectives in Neuroimmunomodulation
    4. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    5. Article: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    6. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    7. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advances: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    8. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    9. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Sex Hormones, NOS, and Immunity
    10. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Nervous System Inputs to Inflammation
    11. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Apoptosis, Glucocorticoids, and Thymic Immunity
    12. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Melatonin, MSH, Opiates, and Immune Function
    13. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Hypothalamic-Pituitary-Adrenal Axis and Glucocorticoids
    14. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Thymus-Neuroendocrine Interactions
    15. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Growth Hormone, Prolactin, and POMC
    16. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: VIP, Substance P, and Calcitonin
    17. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications
    18. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Behavior and the Immune System: Animal Models
    19. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Human Behavior and Immune Responses
    20. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Inflammatory Diseases: Human and Animal Models
    21. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Allergic Disease
    22. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Infectious Diseases
    1. The Reactivity of the Cardiovascular System and Immunomodulation by Catecholamines in Juvenile Chronic Arthritis (pages 698–704)

      ANNEMIEKE KAVELAARS, TEAU de JONG-de VOS van STEENWIJK, WIETSE KUIS and COBI J. HEIJNEN

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09608.x

    2. Neuroendocrine Influences on Experimental Autoimmune Encephalomyelitis (pages 705–716)

      CAROLINE C. WHITACRE, KENNICHI DOWDELL and ANN C. GRIFFIN

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09609.x

  20. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Allergic Disease

    1. Top of page
    2. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Introduction
    3. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: New Perspectives in Neuroimmunomodulation
    4. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    5. Article: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    6. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    7. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advances: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    8. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    9. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Sex Hormones, NOS, and Immunity
    10. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Nervous System Inputs to Inflammation
    11. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Apoptosis, Glucocorticoids, and Thymic Immunity
    12. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Melatonin, MSH, Opiates, and Immune Function
    13. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Hypothalamic-Pituitary-Adrenal Axis and Glucocorticoids
    14. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Thymus-Neuroendocrine Interactions
    15. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Growth Hormone, Prolactin, and POMC
    16. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: VIP, Substance P, and Calcitonin
    17. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications
    18. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Behavior and the Immune System: Animal Models
    19. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Human Behavior and Immune Responses
    20. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Inflammatory Diseases: Human and Animal Models
    21. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Allergic Disease
    22. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Infectious Diseases
    1. Mechanisms of Glucocorticoid-Resistant Asthma (pages 735–746)

      DONALD Y. M. LEUNG, MARGARET de CASTRO, STANLEY J. SZEFLER and GEORGE P. CHROUSOS

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09612.x

    2. Interleukin-1 Receptor Defect in Autoimmune NZB Mouse Brain (pages 755–761)

      FRANCE HAOUR, MEHRNAZ JAFARIAN-TEHRANI, MARIE-MADELEINE GABELLEC, MICHELE CRUMEYROLLE-ARIAS, YANHUA HU, GEORG WICK and THERESE TERNYNCK

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09614.x

    3. Effects of Prolactin in Stimulating Disease Activity in Systemic Lupus Erythematosus (pages 762–772)

      SARA E. WALKER, ROBERT W. MCMURRAY, JOHN M. HOURI, SUSAN H. ALLEN, DUANE KEISLER, GORDON C. SHARP and JANET A. SCHLECHTE

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09615.x

  21. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Infectious Diseases

    1. Top of page
    2. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Introduction
    3. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: New Perspectives in Neuroimmunomodulation
    4. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    5. Article: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and the Central Nervous System
    6. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    7. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advances: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    8. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Cytokines and Endocrine Function
    9. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part I. Molecular Aspects of Neuroimmunomodulation: Sex Hormones, NOS, and Immunity
    10. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Nervous System Inputs to Inflammation
    11. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Apoptosis, Glucocorticoids, and Thymic Immunity
    12. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Melatonin, MSH, Opiates, and Immune Function
    13. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Hypothalamic-Pituitary-Adrenal Axis and Glucocorticoids
    14. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Thymus-Neuroendocrine Interactions
    15. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: Growth Hormone, Prolactin, and POMC
    16. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part II. Integrative Aspects of Neuroimmunomodulation: VIP, Substance P, and Calcitonin
    17. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications
    18. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Behavior and the Immune System: Animal Models
    19. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Human Behavior and Immune Responses
    20. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Inflammatory Diseases: Human and Animal Models
    21. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Allergic Disease
    22. Neuroimmunomodulation: Molecular Aspects, Integrative Systems, and Clinical Advancesa: Part III. Disturbances in Neuroendocrine-Immune Interactions: Clinical, Behavioral, and Therapeutic Implications: Stress, Neuroendocrine Responses, and Infectious Diseases
    1. Host Resistance to Mycobacteria Is Compromised by Activation of the Hypothalamic-Pituitary-Adrenal Axis (pages 773–786)

      DAVID H. BROWN, WILLIAM P. LAFUSE and BRUCE S. ZWILLING

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09616.x

    2. Neurohormonal Host Defense in Endotoxin Shock (pages 787–802)

      ISTVAN BERCZI

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09617.x

    3. Stress-Induced Neuroendocrine Modulation of Viral Pathogenesis and Immunity (pages 803–808)

      JOHN F. SHERIDAN, CATHLEEN DOBBS, JAEHO JUNG, XIAOHONG CHU, ALEXANDRIA KONSTANTINOS, DAVID PADGETT and RONALD GLASER

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09618.x

    4. Neuroendocrine Dysfunction in African Trypanosomiasis: The Role of Cytokines (pages 809–821)

      MARTIN REINCKE, WIEBKE ARLT, CHRISTINA HEPPNER, FRANK PETZKE, GEORGE P. CHROUSOS and BRUNO ALLOLIO

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09619.x

    5. The Encephalopathy Associated with Murine Acquired Immunodeficiency Syndrome (pages 822–834)

      YOSHITATSU SEI, YELENA KUSTOVA, YONG LI, HERBERT C. MORSE III, PHIL SKOLNICK and ANTHONY S. BASILE

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09620.x

    6. Glucocorticoid Resistance and the Immune Function in the Immunodeficiency Syndrome (pages 835–847)

      GUIDO NORBIATO, MAURIZIO BEVILACQUA, TARCISIO VAGO and MARIO CLERICI

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09621.x

    7. The Neuropeptide α-MSH in HIV Infection and Other Disorders in Humans (pages 848–856)

      ANNA CATANIA, LORENA AIRAGHI, LETIZIA GAROFALO, MARIAGRAZIA CUTULI and JAMES M. LIPTON

      Version of Record online: 7 FEB 2006 | DOI: 10.1111/j.1749-6632.1998.tb09622.x

SEARCH

SEARCH BY CITATION